BRPI0807227A2 - métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida - Google Patents

métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida

Info

Publication number
BRPI0807227A2
BRPI0807227A2 BRPI0807227A BRPI0807227A BRPI0807227A2 BR PI0807227 A2 BRPI0807227 A2 BR PI0807227A2 BR PI0807227 A BRPI0807227 A BR PI0807227A BR PI0807227 A BRPI0807227 A BR PI0807227A BR PI0807227 A2 BRPI0807227 A2 BR PI0807227A2
Authority
BR
Brazil
Prior art keywords
origin
carcinoma
identifying
carcinomas
biomarkers
Prior art date
Application number
BRPI0807227A
Other languages
English (en)
Inventor
Mazumder Abhijit
Talantov Dmitri
F Baden Jonathan
Jatkoe Timothy
Wang Yixin
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of BRPI0807227A2 publication Critical patent/BRPI0807227A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida. a presente invenção refere-se a um método de identificação da origem de uma metástase de origem desconhecida através de obtenção de uma amostra contendo células metastáticas; medição de biomarcadores associados a pelo menos dois carcinomas diferentes; combinação dos dados dos biomarcadores em uma análise de discriminação linear, onde a análise de discriminação linear normaliza os biomarcadores contra uma referência; e impõe um corte o qual otimiza a sensibilidade e especificidade de cada biomarcador, pondera a prevalência dos carcinomas e seleciona um tecido de origem; determinação da origem baseada na maior probabilidade determinada pela análise de discriminação linear ou determinação de que o carcinoma não é derivado de um conjunto particular de carcinomas; e, opcionalmente, medição de biomarcadores específicos para um ou mais carcinomas diferentes adicionais e repetição das etapas para biomarcadores adicionais.
BRPI0807227A 2007-02-01 2008-02-01 métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida BRPI0807227A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88762507P 2007-02-01 2007-02-01
PCT/US2008/052741 WO2008095152A2 (en) 2007-02-01 2008-02-01 Methods and materials for identifying the origin of a carcinoma of unknown primary origin

Publications (1)

Publication Number Publication Date
BRPI0807227A2 true BRPI0807227A2 (pt) 2019-01-22

Family

ID=39674806

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807227A BRPI0807227A2 (pt) 2007-02-01 2008-02-01 métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida

Country Status (8)

Country Link
US (2) US20100021886A1 (pt)
EP (1) EP2125034A4 (pt)
JP (1) JP5666136B2 (pt)
CN (1) CN101687050A (pt)
BR (1) BRPI0807227A2 (pt)
CA (1) CA2677118A1 (pt)
MX (1) MX2009008307A (pt)
WO (1) WO2008095152A2 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2402758B1 (en) * 2005-09-19 2014-09-10 Janssen Diagnostics, LLC Methods and uses for identifying the origin of a carcinoma of unknown primary origin
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2228451A1 (en) * 2009-03-11 2010-09-15 Universiteit Maastricht Method for determining the primary site of cup
WO2011163627A2 (en) * 2010-06-24 2011-12-29 Integrated Diagnostics, Inc. Organ specific diagnostic panels and methods for identification of organ specific panel proteins
MX2013008833A (es) * 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
US10716374B1 (en) 2013-11-27 2020-07-21 Rania Salibi Reconfigurable bag
JP6384930B2 (ja) * 2014-03-25 2018-09-05 ファイブスリー ジェノミックス， エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ がん遺伝子変異の機能確認におけるｒｎａ解析のためのシステムおよび方法
EP3273974A4 (en) * 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapy for malignant disease
CN105400880B (zh) * 2015-12-11 2018-07-17 天津市人民医院 急性心肌梗死早期诊断标志物
TWI725248B (zh) * 2016-10-28 2021-04-21 茂英基因科技股份有限公司 辨識轉移性腫瘤的原發位置之方法及系統
CN110177887B (zh) 2016-11-10 2024-10-29 达丽斯生物医学公司 用于扩增和检测沙眼衣原体的多核苷酸
CN106755395B (zh) * 2016-12-16 2020-05-12 山东第一医科大学(山东省医学科学院) Xi型成骨不全致病基因fkbp10的突变位点及其应用
US10450616B1 (en) 2018-05-09 2019-10-22 Talis Biomedical Corporation Polynucleotides for the amplification and detection of Chlamydia trachomatis
US11891662B2 (en) * 2019-12-02 2024-02-06 Talis Biomedical Corporation Polynucleotides for amplification and detection of human beta actin
US11047007B1 (en) 2020-03-23 2021-06-29 Talis Biomedical Corporation Polynucleotides for amplification and detection of SARS-CoV-2
CN121227943B (zh) * 2025-12-02 2026-04-03 中国农业科学院油料作物研究所 一种花生晚斑病抗性相关分子标记及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
WO2004081564A1 (en) * 2003-03-14 2004-09-23 Peter Maccallum Cancer Institute Expression profiling of tumours
BRPI0512587A (pt) * 2004-06-25 2007-09-18 Veridex Llc processo e reagentes para detecção de melanoma
EP2402758B1 (en) * 2005-09-19 2014-09-10 Janssen Diagnostics, LLC Methods and uses for identifying the origin of a carcinoma of unknown primary origin

Also Published As

Publication number Publication date
EP2125034A4 (en) 2010-01-27
JP5666136B2 (ja) 2015-02-12
CA2677118A1 (en) 2008-08-07
US20100021886A1 (en) 2010-01-28
WO2008095152A2 (en) 2008-08-07
CN101687050A (zh) 2010-03-31
JP2010517536A (ja) 2010-05-27
MX2009008307A (es) 2009-08-25
US20170073758A1 (en) 2017-03-16
EP2125034A2 (en) 2009-12-02
WO2008095152A3 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
BRPI0807227A2 (pt) métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida
Ji et al. Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multicentre study
Iseki et al. Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer
EP2402758A3 (en) Methods and materials for identifying the origin of a carcinoma of unknown primary origin
Weber et al. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis
JP2020514689A5 (pt)
Wang et al. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma
MX357119B (es) Microarn plasmáticos para la detección de cáncer colorrectal temprano.
BR122019023720A8 (pt) Kit de triagem de um indivíduo em uma população por meio de avaliação ou prognóstico do risco de um evento cardiovascular futuro dentro de um período de 5 anos
JP2013542452A5 (pt)
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
DK1776587T3 (da) Anvendelse af C3a og derivater deraf som biomarkör for colorektalt adenom og/eller carcinom, diagnosemetoder og assays under anvendelse deraf
Ikeda et al. Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy
Wang et al. Circulating cell free DNA as the diagnostic marker for colorectal cancer: a systematic review and meta-analysis
Wang et al. The urinary sarcosine/creatinine ratio is a potential diagnostic and prognostic marker in prostate cancer
Kuang et al. CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis
Xu et al. Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients
Leitao et al. Quantifying mRNA and microRNA with qPCR in cervical carcinogenesis: a validation of reference genes to ensure accurate data
Zhang et al. Expression and significance of squalene epoxidase in squamous lung cancerous tissues and pericarcinoma tissues
Zuo et al. The value of microRNAs as the novel biomarkers for colorectal cancer diagnosis: a meta-analysis
Lundgren et al. Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer
Wang et al. Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: a meta-analysis
Wu et al. The prediction of epidermal growth factor receptor mutation and prognosis of EGFR tyrosine kinase inhibitor by serum ferritin in advanced NSCLC
Sultana et al. Quantitative analysis of serum cell-free DNA as a predictive and prognostic marker in breast cancer patients
Critselis et al. Diagnostic and prognostic performance of secreted protein acidic and rich in cysteine (SPARC) assay for detecting primary and recurrent urinary bladder cancer

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 60/887,625 DE 01/02/2007, POR NAO CUMPRIMENTO DE EXIGENCIA RELATIVA A REIVINDICACAO DE PRIORIDADE.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]